• LongBio Pharma was added to the eligible securities lists for Shanghai-Hong Kong Stock Connect, effective Sept. 7, 2026.
• The stock was also included in the eligible securities lists for Shenzhen-Hong Kong Stock Connect, effective the same date.
• Mainland investors can now trade the Hong Kong-listed shares through the Shanghai Stock Exchange or Shenzhen Stock Exchange via Stock Connect.
• The inclusion broadens access to the shares, potentially lifting liquidity and expanding the investor base.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longbio Pharma (Suzhou) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260907-12323917), on September 07, 2026, and is solely responsible for the information contained therein.